10-Q · November 12, 2025
The extracted filing section contains no income statement, balance sheet, cash flow, segment, or quantitative outlook data, so operating and financial trends cannot be assessed. Management reported effective disclosure…
Earnings analysis · 10-K
KRSA earnings analysis
Filed March 30, 2026 · Our reading of the company's report
The latest report
Cyclerion is repositioning around CYC-126 for treatment-resistant depression, supported by the MIT license and a January 2026 Medsteer collaboration, with a planned Phase 2 proof-of-concept study in the second half of…
Read full summary
Cyclerion is repositioning around CYC-126 for treatment-resistant depression, supported by the MIT license and a January 2026 Medsteer collaboration, with a planned Phase 2 proof-of-concept study in the second half of 2026. Revenue was modestly higher at $2.074 million, and operating cash burn improved 24% to $3.314 million, but the company remained loss-making with a $3.528 million net loss and only $3.240 million of cash. The explicit going-concern qualification, expected funding runway through mid-2026, reliance on dilutive equity financing and early-stage pipeline make the risk-reward profile bearish despite potential milestone upside from praliciguat.
Reported figures
- Earnings per share
- $-1.11
- Operating margin
- -239.8%
- Segment
- Single operating segment: revenue of $2.074 million in 2025 versus $2.000 million in 2024; the company manages and evaluates performance on a consolidated basis.
What stood out
-
CYC-126 becomes foundational program
Strategic repositioning toward neuropsychiatric therapeutics is progressing: the company prioritized CYC-126 as its foundational treatment-resistant depression program, licensed supporting intellectual property from MIT in September 2025, and intends to initiate a Phase 2 proof-of-concept study in Australia in the second half of 2026.
-
Praliciguat milestone opportunity expands
Praliciguat generated a $1.0 million development milestone in 2025 after Akebia initiated a U.S. Phase 2 trial for FSGS; Cyclerion is eligible for up to approximately $557.5 million of additional potential development, regulatory and commercialization milestones plus tiered royalties ranging from mid-single digits to 20%.
-
Revenue modestly increases
Revenue increased to $2.074 million in 2025 from $2.000 million in 2024, supported by $0.8 million from the Akebia material purchase agreement and $1.0 million from the praliciguat license milestone.
-
Cash burn and per-share loss improve
Operating cash burn improved to $3.314 million in 2025 from $4.333 million in 2024, a reduction of $1.019 million or 24%, while net loss per share improved to $(1.11) from $(1.21), despite the net loss increasing to $3.528 million from $3.057 million.
-
Legacy assets advance through Tisento
Tisento advanced legacy assets externally: its global Phase 2b PRIZM study of zagociguat enrolled approximately 44 participants, received FDA Fast Track designation in June 2025, and completed enrollment in January 2026. Cyclerion retains a 10% equity interest in Tisento Parent carried at $5.35 million.
-
Lean model supports portfolio flexibility
The company maintained a lean structure with one employee as of December 31, 2025 and outsourced laboratory work; it also added Medsteer collaboration and option rights in January 2026 to access technology, software, data and know-how related to anesthetic delivery and physiological monitoring.
What to watch
-
Going-concern and liquidity risk
Management concluded that substantial doubt exists about continuing as a going concern. Cash and cash equivalents were $3.240 million at December 31, 2025, and are expected to fund operations only through mid-2026; the company expects continuing operating losses and must obtain additional funding.
-
Equity financing may cause dilution
Future financing is likely to dilute shareholders: in 2025 the company issued 499,998 private-placement shares for gross proceeds of approximately $1.375 million and sold 715,220 ATM shares for net proceeds of $2.1 million; it also sold 405,000 additional ATM shares for approximately $0.8 million on January 6, 2026 and exhausted the 2025 Shelf.
-
Early-stage pipeline and approval risk
CYC-126 remains an early-stage development program with substantial execution and regulatory uncertainty. The company states it cannot estimate the timing or cost of approval and plans only to initiate a Phase 2 proof-of-concept study in the second half of 2026; the MIT license carries up to $4.4 million of development, regulatory and sales milestones and low-single-digit royalties.
-
Unpredictable licensing revenue base
Revenue is dependent on episodic licensing and asset transactions rather than product sales: 2025 revenue included $1.0 million from a praliciguat milestone, $0.8 million from development materials and $0.3 million from olinciguat option-related fees, while the olinciguat option terminated on October 23, 2025.
-
Illiquid Tisento investment exposure
The $5.35 million Tisento Parent investment has no readily determinable fair value and is exposed to impairment risk. The filing identifies Tisento as a startup requiring significant capital to advance programs and states that Cyclerion’s maximum exposure to loss is the investment’s carrying amount.
Management's outlook
No quantitative annual revenue or EPS guidance is provided. Management states that cash and cash equivalents as of December 31, 2025 are expected to fund operations through mid-2026, and that a Phase 2 proof-of-concept study for CYC-126 is intended to begin in Australia in the second half of 2026.
Earlier filings 1
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.